九州通(600998.SH):產品呋塞米注射液擬中標第八批集中採購
格隆匯3月30日丨九州通(600998.SH)公佈,公司子公司北京京豐製藥集團有限公司(簡稱“北京京豐”)參加了國家組織藥品集中採購和使用聯合採購辦公室組織的第八批全國藥品集中採購的投標,北京京豐的產品呋塞米注射液擬中標本次集中採購,該產品品為利尿劑,適用於水腫性疾病、高血壓、預防急性腎功能衰竭、高鉀血癥及高鈣血癥、稀釋性低鈉血癥、抗利尿激素分泌過多(SIADH)、急性藥物毒物中毒。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.